<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00818623</url>
  </required_header>
  <id_info>
    <org_study_id>FE200486 CS07</org_study_id>
    <nct_id>NCT00818623</nct_id>
  </id_info>
  <brief_title>Investigation of a New Trial Drug (FE200486) in Prostate Cancer Patients</brief_title>
  <official_title>An Open-Label, Multi-Center, Parallel and Sequential, Ascending Single Dose Study Investigating the Pharmacokinetics, Pharmacodynamics and Safety of FE200486 in Prostate Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ferring Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ferring Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial was to find an optimal dose for a new trial drug - degarelix
      (FE200486) - in the treatment of prostate cancer. Furthermore the safety of the drug was
      studied. Patients participating were treated with FE200486 on one occasion. Thereafter they
      came in for visits following a specific schedule until blood samples showed that there was no
      further effect.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Degarelix was not FDA regulated at the time of the trial. After completion of the trial
      degarelix has been approved by the FDA and is thus an FDA regulated intervention.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2002</start_date>
  <completion_date type="Actual">October 2004</completion_date>
  <primary_completion_date type="Actual">October 2004</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time From Dosing Until Testosterone Levels &gt;0.5 ng/mL</measure>
    <time_frame>3 months</time_frame>
    <description>Intent-to-treat (ITT) population. This outcome measure is based on one testosterone value &gt;0.5 ng/mL at Day 28 onwards.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Testosterone Level ≤0.5 ng/mL for at Least 28 Days</measure>
    <time_frame>Two - six months</time_frame>
    <description>The table shows the number of participants with testosterone level ≤0.5 ng/mL for at least 28 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Testosterone Level ≤0.5 ng/mL for at Least 84 Days</measure>
    <time_frame>3 months</time_frame>
    <description>The table shows the number of participants with testosterone level ≤0.5 ng/mL for at least 84 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Testosterone Castration (Testosterone ≤0.5 ng/mL)</measure>
    <time_frame>3 months</time_frame>
    <description>Time to testosterone castration was calculated as the number of days from dosing to the first scheduled visit when testosterone was less than 0.5 ng/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to 50% Reduction in Prostate-specific Antigen Levels</measure>
    <time_frame>3 months</time_frame>
    <description>The time to 50% prostate-specific antigen (PSA) reduction from baseline was defined as the number of days from dosing to the first visit where a 50% reduction in PSA level was reached.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to 90% Reduction in Prostate-specific Antigen Levels</measure>
    <time_frame>3 months</time_frame>
    <description>The time to 90% prostate-specific antigen (PSA) reduction from baseline was defined as the number of days from dosing to the first visit where a 90% reduction in PSA level was reached.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Liver Function Tests</measure>
    <time_frame>3 months</time_frame>
    <description>The figures presents the number of participants who had abnormal (defined as above upper limit of normal range (ULN)) alanine aminotransferase (ALT) levels, aspartate aminotransferase levels, and bilirubin levels plus the number of participants who had ALT increases &gt;3x ULN and ALT increases &gt;3x ULN with concurrently increased bilirubin &gt;1.5 ULN.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants With Markedly Abnormal Change in Vital Signs and Body Weight</measure>
    <time_frame>3 months</time_frame>
    <description>Vital signs and body weight included incidence of markedly abnormal changes in blood pressure (systolic and diastolic), pulse, and body weight at the end of trial as compared to baseline. The table presents the number of participants in each group with normal baseline and markedly abnormal value post-baseline.</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">172</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Degarelix 120 mg (20 mg/mL)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Degarelix 120 mg (20 mg/mL)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Degarelix 120 mg (40 mg/mL)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Degarelix 120 mg (40 mg/mL)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Degarelix 160 mg (40 mg/mL)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Degarelix 160 mg (40 mg/mL)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Degarelix 200 mg (40 mg/mL)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Degarelix 200 mg (40 mg/mL)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Degarelix 200 mg (60 mg/mL)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Degarelix 200 mg (60 mg/mL)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Degarelix 240 mg (40 mg/mL)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Degarelix 240 mg (40 mg/mL)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Degarelix 240 mg (60 mg/mL)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Degarelix 240 mg (60 mg/mL)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Degarelix 320 mg (60 mg/mL)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Degarelix 320 mg (60 mg/mL)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Degarelix</intervention_name>
    <description>Degarelix (120 mg (20 mg/mL)) was given as a subcutaneous injection</description>
    <arm_group_label>Degarelix 120 mg (20 mg/mL)</arm_group_label>
    <other_name>FE200486</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Degarelix</intervention_name>
    <description>Degarelix (120 mg (40 mg/mL)) was given as a subcutaneous injection</description>
    <arm_group_label>Degarelix 120 mg (40 mg/mL)</arm_group_label>
    <other_name>FE200486</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Degarelix</intervention_name>
    <description>Degarelix (160 mg (40 mg/mL)) was given as a subcutaneous injection</description>
    <arm_group_label>Degarelix 160 mg (40 mg/mL)</arm_group_label>
    <other_name>FE200486</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Degarelix</intervention_name>
    <description>Degarelix (200 mg (40 mg/mL)) was given as a subcutaneous injection</description>
    <arm_group_label>Degarelix 200 mg (40 mg/mL)</arm_group_label>
    <other_name>FE200486</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Degarelix</intervention_name>
    <description>Degarelix (200 mg (60 mg/mL)) was given as a subcutaneous injection</description>
    <arm_group_label>Degarelix 200 mg (60 mg/mL)</arm_group_label>
    <other_name>FE200486</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Degarelix</intervention_name>
    <description>Degarelix (240 mg (40 mg/mL)) was given as a subcutaneous injection</description>
    <arm_group_label>Degarelix 240 mg (40 mg/mL)</arm_group_label>
    <other_name>FE200486</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Degarelix</intervention_name>
    <description>Degarelix (240 mg (60 mg/mL)) was given as a subcutaneous injection</description>
    <arm_group_label>Degarelix 240 mg (60 mg/mL)</arm_group_label>
    <other_name>FE200486</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Degarelix</intervention_name>
    <description>Degarelix (320 mg (60 mg/mL)) was given as a subcutaneous injection</description>
    <arm_group_label>Degarelix 320 mg (60 mg/mL)</arm_group_label>
    <other_name>FE200486</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent obtained before any trial related procedures

          -  Male patient with proven prostate cancer in need for endocrine treatment, except for
             neoadjuvant hormonal therapy

          -  ECOG score to be equal to or above 2

          -  Testosterone level within age-specific normal range

          -  PSA value equal to or above 2 ng/ml

          -  Life expectancy of at least 6 months

        Exclusion Criteria:

          -  Previous or current hormonal treatment of prostate cancer

          -  Recent or current treatment with any drugs modifying the testosterone level

          -  Candidate for curative treatment such as prostatectomy or radiotherapy

          -  History of severe asthma, anaphylactic reactions or Quincke's Oedema

          -  Hypersensitivity towards any component of FE200486

          -  Cancer disease within the last ten years except for prostate cancer and some skin
             cancers

          -  Signs of liver impairment shown as elevated serum ALT or serum bilirubin

          -  Other laboratory abnormalities that judged by the investigator would interfere with
             the patients participation in the trial or the evaluation of the trial results

          -  Presenting with significant neurological, gastrointestinal, renal, hepatic,
             cardiovascular, psychological, pulmonary, metabolic, endocrine, haematological,
             dermatological or infectious disorder. In addition any other condition such as
             excessive alcohol or drug abuse that may interfere with trial participation or
             influence the conclusion of the trial as judged by the investigator

          -  Mental incapacity or language barrier

          -  Having received an investigational product within the last 12 weeks preceding the
             trial

          -  Previous participation in this trial
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Development Support</last_name>
    <role>Study Director</role>
    <affiliation>Ferring Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KAS Glostrup</name>
      <address>
        <city>Glostrup</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KAS Herlev</name>
      <address>
        <city>Herlev</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marian Sairaala</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P-K Keskussairaala</name>
      <address>
        <city>Joensuu</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vuorikadun lääkäriasema</name>
      <address>
        <city>Kuopio</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OYS</name>
      <address>
        <city>Oulu</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kirugikeskus</name>
      <address>
        <city>Seinäjoki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TAYS</name>
      <address>
        <city>Tampere</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bajcsy-Zsilinszky Hospital, Urology</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jahn Ferenc Dél Pesti Hospital, Urology</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Péterfy Hospital, Urology</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bács-Kiskun County Hospital, Urology</name>
      <address>
        <city>Kecskemét</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital of Local Gov. Szeged, Urology</name>
      <address>
        <city>Szeged</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MÁV Hospital, Urology</name>
      <address>
        <city>Szolnok</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sentralsykehuset i Rogland</name>
      <address>
        <city>Stavanger</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CF2 Hospital - Bucharest, Urology</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Th Burghele Hospital</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundeni Hospital - Bucharest, Urology</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>County Hospital - Timisoara, Urology</name>
      <address>
        <city>Timisoara</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Hospital #1, State Med Univ/Urology</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Urology of MoH</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moscow City Hospital #60, Urology</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Hospital #15, Urology Department</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Hospital #26, Urology Department</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska Universitetssjukehuset</name>
      <address>
        <city>Göteborg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helsingborgs Lasaret</name>
      <address>
        <city>Helsingborg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitetssjukehuset, MAS</name>
      <address>
        <city>Malmö</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Akademiska Sjukhuset Uppsala</name>
      <address>
        <city>Uppsala</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital, Örebro</name>
      <address>
        <city>Örebro</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Finland</country>
    <country>Hungary</country>
    <country>Norway</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>May 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 7, 2009</study_first_submitted>
  <study_first_submitted_qc>January 7, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 8, 2009</study_first_posted>
  <results_first_submitted>January 22, 2009</results_first_submitted>
  <results_first_submitted_qc>March 30, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 31, 2009</results_first_posted>
  <last_update_submitted>May 18, 2011</last_update_submitted>
  <last_update_submitted_qc>May 18, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 23, 2011</last_update_posted>
  <responsible_party>
    <name_title>Clinical Development Support</name_title>
    <organization>Ferring Pharmaceuticals</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Degarelix 120mg (20mg/mL)</title>
          <description>Degarelix 120 mg (20 mg/mL)</description>
        </group>
        <group group_id="P2">
          <title>Degarelix 120mg (40mg/mL)</title>
          <description>Degarelix 120 mg (40 mg/mL)</description>
        </group>
        <group group_id="P3">
          <title>Degarelix 160mg (40mg/mL)</title>
          <description>Degarelix 160 mg (40 mg/mL)</description>
        </group>
        <group group_id="P4">
          <title>Degarelix 200mg (40mg/mL)</title>
          <description>Degarelix 200 mg (40 mg/mL)</description>
        </group>
        <group group_id="P5">
          <title>Degarelix 200mg (60mg/mL)</title>
          <description>Degarelix 200 mg (60 mg/mL)</description>
        </group>
        <group group_id="P6">
          <title>Degarelix 240mg (40mg/mL)</title>
          <description>Degarelix 240 mg (40 mg/mL)</description>
        </group>
        <group group_id="P7">
          <title>Degarelix 240mg (60mg/mL)</title>
          <description>Degarelix 240 mg (60 mg/mL)</description>
        </group>
        <group group_id="P8">
          <title>Degarelix 320mg (60mg/mL)</title>
          <description>Degarelix 320 mg (60 mg/mL)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="24"/>
                <participants group_id="P5" count="27"/>
                <participants group_id="P6" count="24"/>
                <participants group_id="P7" count="27"/>
                <participants group_id="P8" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Intent-to-treat (ITT) Population</title>
              <participants_list>
                <participants group_id="P1" count="25">One participant in this group was randomized but never received any treatment.</participants>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="12">One participant in this group was randomized but never received any treatment.</participants>
                <participants group_id="P4" count="24"/>
                <participants group_id="P5" count="24">Three participants in this group were randomized but never received any treatment.</participants>
                <participants group_id="P6" count="24"/>
                <participants group_id="P7" count="24">Three participants in this group were randomized but never received any treatment.</participants>
                <participants group_id="P8" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="19"/>
                <participants group_id="P5" count="23"/>
                <participants group_id="P6" count="21"/>
                <participants group_id="P7" count="23"/>
                <participants group_id="P8" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="4"/>
                <participants group_id="P8" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Bad prostate specific antigen response</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Need of additional treatment</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of trial drug at site</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Disease progression</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Degarelix 120mg (20mg/mL)</title>
          <description>Degarelix 120 mg (20 mg/mL)</description>
        </group>
        <group group_id="B2">
          <title>Degarelix 120mg (40mg/mL)</title>
          <description>Degarelix 120 mg (40 mg/mL)</description>
        </group>
        <group group_id="B3">
          <title>Degarelix 160mg (40mg/mL)</title>
          <description>Degarelix 160 mg (40 mg/mL)</description>
        </group>
        <group group_id="B4">
          <title>Degarelix 200mg (40mg/mL)</title>
          <description>Degarelix 200 mg (40 mg/mL)</description>
        </group>
        <group group_id="B5">
          <title>Degarelix 200mg (60mg/mL)</title>
          <description>Degarelix 200 mg (60 mg/mL)</description>
        </group>
        <group group_id="B6">
          <title>Degarelix 240mg (40mg/mL)</title>
          <description>Degarelix 240 mg (40 mg/mL)</description>
        </group>
        <group group_id="B7">
          <title>Degarelix 240mg (60mg/mL)</title>
          <description>Degarelix 240 mg (60 mg/mL)</description>
        </group>
        <group group_id="B8">
          <title>Degarelix 320mg (60mg/mL)</title>
          <description>Degarelix 320 mg (60 mg/mL)</description>
        </group>
        <group group_id="B9">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="12"/>
            <count group_id="B4" value="24"/>
            <count group_id="B5" value="24"/>
            <count group_id="B6" value="24"/>
            <count group_id="B7" value="24"/>
            <count group_id="B8" value="27"/>
            <count group_id="B9" value="172"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="6"/>
                    <measurement group_id="B9" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="22"/>
                    <measurement group_id="B5" value="20"/>
                    <measurement group_id="B6" value="22"/>
                    <measurement group_id="B7" value="18"/>
                    <measurement group_id="B8" value="21"/>
                    <measurement group_id="B9" value="143"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70.0" spread="10.3"/>
                    <measurement group_id="B2" value="73.8" spread="3.97"/>
                    <measurement group_id="B3" value="70.1" spread="8.08"/>
                    <measurement group_id="B4" value="74.3" spread="6.48"/>
                    <measurement group_id="B5" value="71.5" spread="8.27"/>
                    <measurement group_id="B6" value="73.1" spread="5.96"/>
                    <measurement group_id="B7" value="71.7" spread="9.54"/>
                    <measurement group_id="B8" value="71.1" spread="6.87"/>
                    <measurement group_id="B9" value="71.9" spread="7.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="24"/>
                    <measurement group_id="B5" value="24"/>
                    <measurement group_id="B6" value="24"/>
                    <measurement group_id="B7" value="24"/>
                    <measurement group_id="B8" value="27"/>
                    <measurement group_id="B9" value="172"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="24"/>
                    <measurement group_id="B5" value="24"/>
                    <measurement group_id="B6" value="24"/>
                    <measurement group_id="B7" value="24"/>
                    <measurement group_id="B8" value="27"/>
                    <measurement group_id="B9" value="172"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Curative intent</title>
          <description>A curative intent of Yes refers to participants who have been castrated via radical prostatectomy or radiotherapy.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="21"/>
                    <measurement group_id="B5" value="23"/>
                    <measurement group_id="B6" value="24"/>
                    <measurement group_id="B7" value="24"/>
                    <measurement group_id="B8" value="26"/>
                    <measurement group_id="B9" value="165"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gleason score</title>
          <description>The Gleason score is a system of grading the aggressiveness of the prostate cancer and how fast it is likely to grow and spread. Scale is 2-10, with low numbers being the least aggressive and 10 being the most aggressive.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>0-1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2-4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="5"/>
                    <measurement group_id="B8" value="12"/>
                    <measurement group_id="B9" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5-6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="6"/>
                    <measurement group_id="B9" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7-10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="17"/>
                    <measurement group_id="B5" value="16"/>
                    <measurement group_id="B6" value="16"/>
                    <measurement group_id="B7" value="13"/>
                    <measurement group_id="B8" value="9"/>
                    <measurement group_id="B9" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Stage of prostate cancer</title>
          <description>Prostate cancer stage was classified to describe the extent of cancer. Localized refers to tumors without involvement of lymph nodes or metastasis. Advanced localized can be larger tumors that may involve the lymph nodes but no metastasis. Metastatic are more advanced cancers that are spreading beyond the original tumor.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Localized</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="8"/>
                    <measurement group_id="B8" value="14"/>
                    <measurement group_id="B9" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Locally advanced</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="10"/>
                    <measurement group_id="B7" value="5"/>
                    <measurement group_id="B8" value="9"/>
                    <measurement group_id="B9" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metastatic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="12"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="10"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not classifiable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body mass index</title>
          <units>kilgram per square meter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.2" spread="2.97"/>
                    <measurement group_id="B2" value="26.6" spread="4.58"/>
                    <measurement group_id="B3" value="26.3" spread="3.74"/>
                    <measurement group_id="B4" value="25.9" spread="2.99"/>
                    <measurement group_id="B5" value="24.5" spread="2.92"/>
                    <measurement group_id="B6" value="26.9" spread="3.18"/>
                    <measurement group_id="B7" value="24.8" spread="2.72"/>
                    <measurement group_id="B8" value="27.1" spread="3.63"/>
                    <measurement group_id="B9" value="26.0" spread="3.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Serum prostate-specific antigen levels</title>
          <units>nanogram per milliliter</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.5" lower_limit="3.0" upper_limit="4509"/>
                    <measurement group_id="B2" value="58.8" lower_limit="9.7" upper_limit="5514"/>
                    <measurement group_id="B3" value="109" lower_limit="4.1" upper_limit="1079"/>
                    <measurement group_id="B4" value="32.3" lower_limit="3.8" upper_limit="1474"/>
                    <measurement group_id="B5" value="46.9" lower_limit="2.3" upper_limit="6450"/>
                    <measurement group_id="B6" value="31.0" lower_limit="4.5" upper_limit="357"/>
                    <measurement group_id="B7" value="31.9" lower_limit="5.2" upper_limit="3490"/>
                    <measurement group_id="B8" value="23.8" lower_limit="1.7" upper_limit="731"/>
                    <measurement group_id="B9" value="37.9" lower_limit="1.7" upper_limit="6450"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Serum testosterone levels</title>
          <units>nanogram per milliliter</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.30" lower_limit="2.37" upper_limit="12.5"/>
                    <measurement group_id="B2" value="3.10" lower_limit="1.08" upper_limit="6.91"/>
                    <measurement group_id="B3" value="3.02" lower_limit="1.65" upper_limit="5.12"/>
                    <measurement group_id="B4" value="4.64" lower_limit="1.97" upper_limit="7.93"/>
                    <measurement group_id="B5" value="5.60" lower_limit="3.01" upper_limit="9.36"/>
                    <measurement group_id="B6" value="4.02" lower_limit="1.49" upper_limit="12.5"/>
                    <measurement group_id="B7" value="4.46" lower_limit="1.81" upper_limit="11.2"/>
                    <measurement group_id="B8" value="3.68" lower_limit="1.45" upper_limit="7.26"/>
                    <measurement group_id="B9" value="4.16" lower_limit="1.08" upper_limit="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Time since prostate cancer diagnosis</title>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="83.2" spread="157"/>
                    <measurement group_id="B2" value="65.9" spread="53.5"/>
                    <measurement group_id="B3" value="222" spread="328"/>
                    <measurement group_id="B4" value="146" spread="298"/>
                    <measurement group_id="B5" value="252" spread="560"/>
                    <measurement group_id="B6" value="313" spread="837"/>
                    <measurement group_id="B7" value="121" spread="425"/>
                    <measurement group_id="B8" value="46.6" spread="54.4"/>
                    <measurement group_id="B9" value="156" spread="439"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kilogram</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="77.8" spread="12.4"/>
                    <measurement group_id="B2" value="82.2" spread="12.1"/>
                    <measurement group_id="B3" value="80.7" spread="11.8"/>
                    <measurement group_id="B4" value="78.2" spread="13.7"/>
                    <measurement group_id="B5" value="74.2" spread="9.88"/>
                    <measurement group_id="B6" value="81.5" spread="10.7"/>
                    <measurement group_id="B7" value="73.5" spread="9.55"/>
                    <measurement group_id="B8" value="81.7" spread="11.1"/>
                    <measurement group_id="B9" value="78.4" spread="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time From Dosing Until Testosterone Levels &gt;0.5 ng/mL</title>
        <description>Intent-to-treat (ITT) population. This outcome measure is based on one testosterone value &gt;0.5 ng/mL at Day 28 onwards.</description>
        <time_frame>3 months</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>Degarelix 120mg (20mg/mL)</title>
            <description>Degarelix 120 mg (20 mg/mL)</description>
          </group>
          <group group_id="O2">
            <title>Degarelix 120mg (40mg/mL)</title>
            <description>Degarelix 120 mg (40 mg/mL)</description>
          </group>
          <group group_id="O3">
            <title>Degarelix 160mg (40mg/mL)</title>
            <description>Degarelix 160 mg (40 mg/mL)</description>
          </group>
          <group group_id="O4">
            <title>Degarelix 200mg (40mg/mL)</title>
            <description>Degarelix 200 mg (40 mg/mL)</description>
          </group>
          <group group_id="O5">
            <title>Degarelix 200mg (60mg/mL)</title>
            <description>Degarelix 200 mg (60 mg/mL)</description>
          </group>
          <group group_id="O6">
            <title>Degarelix 240mg (40mg/mL)</title>
            <description>Degarelix 240 mg (40 mg/mL)</description>
          </group>
          <group group_id="O7">
            <title>Degarelix 240mg (60mg/mL)</title>
            <description>Degarelix 240 mg (60 mg/mL)</description>
          </group>
          <group group_id="O8">
            <title>Degarelix 320mg (60mg/mL)</title>
            <description>Degarelix 320 mg (60 mg/mL)</description>
          </group>
        </group_list>
        <measure>
          <title>Time From Dosing Until Testosterone Levels &gt;0.5 ng/mL</title>
          <description>Intent-to-treat (ITT) population. This outcome measure is based on one testosterone value &gt;0.5 ng/mL at Day 28 onwards.</description>
          <population>ITT population.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="24"/>
                <count group_id="O5" value="24"/>
                <count group_id="O6" value="24"/>
                <count group_id="O7" value="24"/>
                <count group_id="O8" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84" lower_limit="63" upper_limit="119"/>
                    <measurement group_id="O2" value="63" lower_limit="28" upper_limit="133"/>
                    <measurement group_id="O3" value="70" lower_limit="28" upper_limit="98"/>
                    <measurement group_id="O4" value="140" lower_limit="112" upper_limit="147"/>
                    <measurement group_id="O5" value="84" lower_limit="35" upper_limit="112"/>
                    <measurement group_id="O6" value="140" lower_limit="112" upper_limit="182"/>
                    <measurement group_id="O7" value="87.5" lower_limit="28" upper_limit="140"/>
                    <measurement group_id="O8" value="133" lower_limit="91" upper_limit="154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0000586</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Testosterone Level ≤0.5 ng/mL for at Least 28 Days</title>
        <description>The table shows the number of participants with testosterone level ≤0.5 ng/mL for at least 28 days.</description>
        <time_frame>Two - six months</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>Degarelix 120mg (20mg/mL)</title>
            <description>Degarelix 120 mg (20 mg/mL)</description>
          </group>
          <group group_id="O2">
            <title>Degarelix 120mg (40mg/mL)</title>
            <description>Degarelix 120 mg (40 mg/mL)</description>
          </group>
          <group group_id="O3">
            <title>Degarelix 160mg (40mg/mL)</title>
            <description>Degarelix 160 mg (40 mg/mL)</description>
          </group>
          <group group_id="O4">
            <title>Degarelix 200mg (40mg/mL)</title>
            <description>Degarelix 200 mg (40 mg/mL)</description>
          </group>
          <group group_id="O5">
            <title>Degarelix 200mg (60mg/mL)</title>
            <description>Degarelix 200 mg (60 mg/mL)</description>
          </group>
          <group group_id="O6">
            <title>Degarelix 240mg (40mg/mL)</title>
            <description>Degarelix 240 mg (40 mg/mL)</description>
          </group>
          <group group_id="O7">
            <title>Degarelix 240mg (60mg/mL)</title>
            <description>Degarelix 240 mg (60 mg/mL)</description>
          </group>
          <group group_id="O8">
            <title>Degarelix 320mg (60mg/mL)</title>
            <description>Degarelix 320 mg (60 mg/mL)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Testosterone Level ≤0.5 ng/mL for at Least 28 Days</title>
          <description>The table shows the number of participants with testosterone level ≤0.5 ng/mL for at least 28 days.</description>
          <population>ITT population.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="24"/>
                <count group_id="O5" value="24"/>
                <count group_id="O6" value="24"/>
                <count group_id="O7" value="24"/>
                <count group_id="O8" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21" lower_limit="66.1" upper_limit="95.8"/>
                    <measurement group_id="O2" value="8" lower_limit="33.7" upper_limit="86.0"/>
                    <measurement group_id="O3" value="6" lower_limit="22.9" upper_limit="78.0"/>
                    <measurement group_id="O4" value="24" lower_limit="85.8" upper_limit="100"/>
                    <measurement group_id="O5" value="18" lower_limit="52.6" upper_limit="87.9"/>
                    <measurement group_id="O6" value="22" lower_limit="72.9" upper_limit="99.4"/>
                    <measurement group_id="O7" value="15" lower_limit="40.3" upper_limit="78.4"/>
                    <measurement group_id="O8" value="24" lower_limit="69.4" upper_limit="96.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0014</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Percentage of participants castrated (testosterone ≤0.5 ng/mL) for at least 28 days.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percentage of participants castrated</param_type>
            <param_value>87.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>66.1</ci_lower_limit>
            <ci_upper_limit>95.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Percentage of participants castrated (testosterone ≤0.5 ng/mL) for at least 28 days.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percentage of participants castrated</param_type>
            <param_value>66.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>33.7</ci_lower_limit>
            <ci_upper_limit>86</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Percentage of participants castrated (testosterone ≤0.5 ng/mL) for at least 28 days.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percentage of participants castrated</param_type>
            <param_value>54.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>22.9</ci_lower_limit>
            <ci_upper_limit>78</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Percentage of participants castrated (testosterone ≤0.5 ng/mL) for at least 28 days.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percentage of participants castrated</param_type>
            <param_value>100</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>85.8</ci_lower_limit>
            <ci_upper_limit>100</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Percentage of participants castrated (testosterone ≤0.5 ng/mL) for at least 28 days.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percentage of participants castrated</param_type>
            <param_value>75</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>52.6</ci_lower_limit>
            <ci_upper_limit>87.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Percentage of participants castrated (testosterone ≤0.5 ng/mL) for at least 28 days.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percentage of participants castrated</param_type>
            <param_value>95.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>72.9</ci_lower_limit>
            <ci_upper_limit>99.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Percentage of participants castrated (testosterone ≤0.5 ng/mL) for at least 28 days.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percentage of participants castrated</param_type>
            <param_value>62.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>40.3</ci_lower_limit>
            <ci_upper_limit>78.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>Percentage of participants castrated (testosterone ≤0.5 ng/mL) for at least 28 days.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percentage of participants castrated</param_type>
            <param_value>88.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>69.4</ci_lower_limit>
            <ci_upper_limit>96.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Testosterone Level ≤0.5 ng/mL for at Least 84 Days</title>
        <description>The table shows the number of participants with testosterone level ≤0.5 ng/mL for at least 84 days.</description>
        <time_frame>3 months</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>Degarelix 120mg (20mg/mL)</title>
            <description>Degarelix 120 mg (20 mg/mL)</description>
          </group>
          <group group_id="O2">
            <title>Degarelix 120mg (40mg/mL)</title>
            <description>Degarelix 120 mg (40 mg/mL)</description>
          </group>
          <group group_id="O3">
            <title>Degarelix 160mg (40mg/mL)</title>
            <description>Degarelix 160 mg (40 mg/mL)</description>
          </group>
          <group group_id="O4">
            <title>Degarelix 200mg (40mg/mL)</title>
            <description>Degarelix 200 mg (40 mg/mL)</description>
          </group>
          <group group_id="O5">
            <title>Degarelix 200mg (60mg/mL)</title>
            <description>Degarelix 200 mg (60 mg/mL)</description>
          </group>
          <group group_id="O6">
            <title>Degarelix 240mg (40mg/mL)</title>
            <description>Degarelix 240 mg (40 mg/mL)</description>
          </group>
          <group group_id="O7">
            <title>Degarelix 240mg (60mg/mL)</title>
            <description>Degarelix 240 mg (60 mg/mL)</description>
          </group>
          <group group_id="O8">
            <title>Degarelix 320mg (60mg/mL)</title>
            <description>Degarelix 320 mg (60 mg/mL)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Testosterone Level ≤0.5 ng/mL for at Least 84 Days</title>
          <description>The table shows the number of participants with testosterone level ≤0.5 ng/mL for at least 84 days.</description>
          <population>ITT population.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="24"/>
                <count group_id="O5" value="24"/>
                <count group_id="O6" value="24"/>
                <count group_id="O7" value="24"/>
                <count group_id="O8" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11" lower_limit="25.6" upper_limit="64"/>
                    <measurement group_id="O2" value="4" lower_limit="12.1" upper_limit="64.3"/>
                    <measurement group_id="O3" value="3" lower_limit="8.3" upper_limit="60.6"/>
                    <measurement group_id="O4" value="20" lower_limit="61.5" upper_limit="93.4"/>
                    <measurement group_id="O5" value="11" lower_limit="28.3" upper_limit="67.4"/>
                    <measurement group_id="O6" value="18" lower_limit="58.8" upper_limit="92.8"/>
                    <measurement group_id="O7" value="12" lower_limit="29.1" upper_limit="67.8"/>
                    <measurement group_id="O8" value="19" lower_limit="49.4" upper_limit="83.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0031</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Percentage of participants castrated (testosterone ≤0.5 ng/mL) for at least 84 days.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percentage of participants castrated</param_type>
            <param_value>45.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>25.6</ci_lower_limit>
            <ci_upper_limit>64</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Percentage of participants castrated (testosterone ≤0.5 ng/mL) for at least 84 days.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percentage of participants castrated</param_type>
            <param_value>38.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>12.1</ci_lower_limit>
            <ci_upper_limit>64.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Percentage of participants castrated (testosterone ≤0.5 ng/mL) for at least 84 days.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percentage of participants castrated</param_type>
            <param_value>32.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>8.3</ci_lower_limit>
            <ci_upper_limit>60.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Percentage of participants castrated (testosterone ≤0.5 ng/mL) for at least 84 days.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percentage of participants castrated</param_type>
            <param_value>83.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>61.5</ci_lower_limit>
            <ci_upper_limit>93.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Percentage of participants castrated (testosterone ≤0.5 ng/mL) for at least 84 days.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percentage of participants castrated</param_type>
            <param_value>49.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>28.3</ci_lower_limit>
            <ci_upper_limit>67.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Percentage of participants castrated (testosterone ≤0.5 ng/mL) for at least 84 days.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percentage of participants castrated</param_type>
            <param_value>82</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>58.8</ci_lower_limit>
            <ci_upper_limit>92.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Percentage of participants castrated (testosterone ≤0.5 ng/mL) for at least 84 days.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percentage of participants castrated</param_type>
            <param_value>50</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>29.1</ci_lower_limit>
            <ci_upper_limit>67.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>Percentage of participants castrated (testosterone ≤0.5 ng/mL) for at least 84 days.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percentage of participants castrated</param_type>
            <param_value>70.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>49.4</ci_lower_limit>
            <ci_upper_limit>83.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Testosterone Castration (Testosterone ≤0.5 ng/mL)</title>
        <description>Time to testosterone castration was calculated as the number of days from dosing to the first scheduled visit when testosterone was less than 0.5 ng/mL.</description>
        <time_frame>3 months</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Degarelix 120mg (20mg/mL)</title>
            <description>Degarelix 120 mg (20 mg/mL)</description>
          </group>
          <group group_id="O2">
            <title>Degarelix 120mg (40mg/mL)</title>
            <description>Degarelix 120 mg (40 mg/mL)</description>
          </group>
          <group group_id="O3">
            <title>Degarelix 160mg (40mg/mL)</title>
            <description>Degarelix 160 mg (40 mg/mL)</description>
          </group>
          <group group_id="O4">
            <title>Degarelix 200mg (40mg/mL)</title>
            <description>Degarelix 200 mg (40 mg/mL)</description>
          </group>
          <group group_id="O5">
            <title>Degarelix 200mg (60mg/mL)</title>
            <description>Degarelix 200 mg (60 mg/mL)</description>
          </group>
          <group group_id="O6">
            <title>Degarelix 240mg (40mg/mL)</title>
            <description>Degarelix 240 mg (40 mg/mL)</description>
          </group>
          <group group_id="O7">
            <title>Degarelix 240mg (60mg/mL)</title>
            <description>Degarelix 240 mg (60 mg/mL)</description>
          </group>
          <group group_id="O8">
            <title>Degarelix 320mg (60mg/mL)</title>
            <description>Degarelix 320 mg (60 mg/mL)</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Testosterone Castration (Testosterone ≤0.5 ng/mL)</title>
          <description>Time to testosterone castration was calculated as the number of days from dosing to the first scheduled visit when testosterone was less than 0.5 ng/mL.</description>
          <population>ITT population</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="24"/>
                <count group_id="O5" value="24"/>
                <count group_id="O6" value="24"/>
                <count group_id="O7" value="24"/>
                <count group_id="O8" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="1" upper_limit="7"/>
                    <measurement group_id="O2" value="1" lower_limit="1" upper_limit="3"/>
                    <measurement group_id="O3" value="1.5" lower_limit="1" upper_limit="2"/>
                    <measurement group_id="O4" value="1.5" lower_limit="1" upper_limit="7"/>
                    <measurement group_id="O5" value="2" lower_limit="1" upper_limit="14"/>
                    <measurement group_id="O6" value="1.5" lower_limit="1" upper_limit="7"/>
                    <measurement group_id="O7" value="2" lower_limit="1" upper_limit="3"/>
                    <measurement group_id="O8" value="1" lower_limit="1" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0866</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to 50% Reduction in Prostate-specific Antigen Levels</title>
        <description>The time to 50% prostate-specific antigen (PSA) reduction from baseline was defined as the number of days from dosing to the first visit where a 50% reduction in PSA level was reached.</description>
        <time_frame>3 months</time_frame>
        <population>ITT population. Patients who did not achieve the actual level of reduction were censored as of the time from dosing for the last available observation.</population>
        <group_list>
          <group group_id="O1">
            <title>Degarelix 120mg (20mg/mL)</title>
            <description>Degarelix 120 mg (20 mg/mL)</description>
          </group>
          <group group_id="O2">
            <title>Degarelix 120mg (40mg/mL)</title>
            <description>Degarelix 120 mg (40 mg/mL)</description>
          </group>
          <group group_id="O3">
            <title>Degarelix 160mg (40mg/mL)</title>
            <description>Degarelix 160 mg (40 mg/mL)</description>
          </group>
          <group group_id="O4">
            <title>Degarelix 200mg (40mg/mL)</title>
            <description>Degarelix 200 mg (40 mg/mL)</description>
          </group>
          <group group_id="O5">
            <title>Degarelix 200mg (60mg/mL)</title>
            <description>Degarelix 200 mg (60 mg/mL)</description>
          </group>
          <group group_id="O6">
            <title>Degarelix 240mg (40mg/mL)</title>
            <description>Degarelix 240 mg (40 mg/mL)</description>
          </group>
          <group group_id="O7">
            <title>Degarelix 240mg (60mg/mL)</title>
            <description>Degarelix 240 mg (60 mg/mL)</description>
          </group>
          <group group_id="O8">
            <title>Degarelix 320mg (60mg/mL)</title>
            <description>Degarelix 320 mg (60 mg/mL)</description>
          </group>
        </group_list>
        <measure>
          <title>Time to 50% Reduction in Prostate-specific Antigen Levels</title>
          <description>The time to 50% prostate-specific antigen (PSA) reduction from baseline was defined as the number of days from dosing to the first visit where a 50% reduction in PSA level was reached.</description>
          <population>ITT population. Patients who did not achieve the actual level of reduction were censored as of the time from dosing for the last available observation.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="24"/>
                <count group_id="O5" value="24"/>
                <count group_id="O6" value="24"/>
                <count group_id="O7" value="24"/>
                <count group_id="O8" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14" lower_limit="7" upper_limit="28"/>
                    <measurement group_id="O2" value="21" lower_limit="7" upper_limit="21"/>
                    <measurement group_id="O3" value="14" lower_limit="7" upper_limit="28"/>
                    <measurement group_id="O4" value="14" lower_limit="7" upper_limit="35"/>
                    <measurement group_id="O5" value="14" lower_limit="7" upper_limit="49"/>
                    <measurement group_id="O6" value="14" lower_limit="7" upper_limit="35"/>
                    <measurement group_id="O7" value="14" lower_limit="7" upper_limit="35"/>
                    <measurement group_id="O8" value="14" lower_limit="7" upper_limit="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.033</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to 90% Reduction in Prostate-specific Antigen Levels</title>
        <description>The time to 90% prostate-specific antigen (PSA) reduction from baseline was defined as the number of days from dosing to the first visit where a 90% reduction in PSA level was reached.</description>
        <time_frame>3 months</time_frame>
        <population>ITT population. Participants who did not achieve the actual level of reduction were censored as of the time from dosing for the last available observation.</population>
        <group_list>
          <group group_id="O1">
            <title>Degarelix 120mg (20mg/mL)</title>
            <description>Degarelix 120 mg (20 mg/mL)</description>
          </group>
          <group group_id="O2">
            <title>Degarelix 120mg (40mg/mL)</title>
            <description>Degarelix 120 mg (40 mg/mL)</description>
          </group>
          <group group_id="O3">
            <title>Degarelix 160mg (40mg/mL)</title>
            <description>Degarelix 160 mg (40 mg/mL)</description>
          </group>
          <group group_id="O4">
            <title>Degarelix 200mg (40mg/mL)</title>
            <description>Degarelix 200 mg (40 mg/mL)</description>
          </group>
          <group group_id="O5">
            <title>Degarelix 200mg (60mg/mL)</title>
            <description>Degarelix 200 mg (60 mg/mL)</description>
          </group>
          <group group_id="O6">
            <title>Degarelix 240mg (40mg/mL)</title>
            <description>Degarelix 240 mg (40 mg/mL)</description>
          </group>
          <group group_id="O7">
            <title>Degarelix 240mg (60mg/mL)</title>
            <description>Degarelix 240 mg (60 mg/mL)</description>
          </group>
          <group group_id="O8">
            <title>Degarelix 320mg (60mg/mL)</title>
            <description>Degarelix 320 mg (60 mg/mL)</description>
          </group>
        </group_list>
        <measure>
          <title>Time to 90% Reduction in Prostate-specific Antigen Levels</title>
          <description>The time to 90% prostate-specific antigen (PSA) reduction from baseline was defined as the number of days from dosing to the first visit where a 90% reduction in PSA level was reached.</description>
          <population>ITT population. Participants who did not achieve the actual level of reduction were censored as of the time from dosing for the last available observation.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="24"/>
                <count group_id="O5" value="24"/>
                <count group_id="O6" value="24"/>
                <count group_id="O7" value="24"/>
                <count group_id="O8" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.5" lower_limit="14" upper_limit="56"/>
                    <measurement group_id="O2" value="35" lower_limit="21" upper_limit="91"/>
                    <measurement group_id="O3" value="42" lower_limit="28" upper_limit="70"/>
                    <measurement group_id="O4" value="35" lower_limit="14" upper_limit="98"/>
                    <measurement group_id="O5" value="28" lower_limit="14" upper_limit="63"/>
                    <measurement group_id="O6" value="42" lower_limit="21" upper_limit="112"/>
                    <measurement group_id="O7" value="35" lower_limit="14" upper_limit="77"/>
                    <measurement group_id="O8" value="45.5" lower_limit="21" upper_limit="112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.131</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluation of Liver Function Tests</title>
        <description>The figures presents the number of participants who had abnormal (defined as above upper limit of normal range (ULN)) alanine aminotransferase (ALT) levels, aspartate aminotransferase levels, and bilirubin levels plus the number of participants who had ALT increases &gt;3x ULN and ALT increases &gt;3x ULN with concurrently increased bilirubin &gt;1.5 ULN.</description>
        <time_frame>3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Degarelix 120mg (20mg/mL)</title>
            <description>Degarelix 120 mg (20 mg/mL)</description>
          </group>
          <group group_id="O2">
            <title>Degarelix 120mg (40mg/mL)</title>
            <description>Degarelix 120 mg (40 mg/mL)</description>
          </group>
          <group group_id="O3">
            <title>Degarelix 160mg (40mg/mL)</title>
            <description>Degarelix 160 mg (40 mg/mL)</description>
          </group>
          <group group_id="O4">
            <title>Degarelix 200mg (40mg/mL)</title>
            <description>Degarelix 200 mg (40 mg/mL)</description>
          </group>
          <group group_id="O5">
            <title>Degarelix 200mg (60mg/mL)</title>
            <description>Degarelix 200 mg (60 mg/mL)</description>
          </group>
          <group group_id="O6">
            <title>Degarelix 240mg (40mg/mL)</title>
            <description>Degarelix 240 mg (40 mg/mL)</description>
          </group>
          <group group_id="O7">
            <title>Degarelix 240mg (60mg/mL)</title>
            <description>Degarelix 240 mg (60 mg/mL)</description>
          </group>
          <group group_id="O8">
            <title>Degarelix 320mg (60mg/mL)</title>
            <description>Degarelix 320 mg (60 mg/mL)</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluation of Liver Function Tests</title>
          <description>The figures presents the number of participants who had abnormal (defined as above upper limit of normal range (ULN)) alanine aminotransferase (ALT) levels, aspartate aminotransferase levels, and bilirubin levels plus the number of participants who had ALT increases &gt;3x ULN and ALT increases &gt;3x ULN with concurrently increased bilirubin &gt;1.5 ULN.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="24"/>
                <count group_id="O5" value="24"/>
                <count group_id="O6" value="24"/>
                <count group_id="O7" value="24"/>
                <count group_id="O8" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Abnormal alanine aminotransferase (ALAT)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="8"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="6"/>
                    <measurement group_id="O8" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abnormal aspartate aminotransferase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="7"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="5"/>
                    <measurement group_id="O8" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abnormal bilirubin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALAT &gt;3x ULN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALAT &gt;3x ULN, bilirubin &gt;1.5x ULN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants With Markedly Abnormal Change in Vital Signs and Body Weight</title>
        <description>Vital signs and body weight included incidence of markedly abnormal changes in blood pressure (systolic and diastolic), pulse, and body weight at the end of trial as compared to baseline. The table presents the number of participants in each group with normal baseline and markedly abnormal value post-baseline.</description>
        <time_frame>3 months</time_frame>
        <population>ITT population. The first value in the category represents the actual clinical reading and the second is the change from baseline for blood pressure (units: millimeters of mercury) and heart rate (units:beats per minute). The weight category includes participants whose percent weight change from baseline fit the stated ranges.</population>
        <group_list>
          <group group_id="O1">
            <title>Degarelix 120mg (20mg/mL)</title>
            <description>Degarelix 120 mg (20 mg/mL)</description>
          </group>
          <group group_id="O2">
            <title>Degarelix 120mg (40mg/mL)</title>
            <description>Degarelix 120 mg (40 mg/mL)</description>
          </group>
          <group group_id="O3">
            <title>Degarelix 160mg (40mg/mL)</title>
            <description>Degarelix 160 mg (40 mg/mL)</description>
          </group>
          <group group_id="O4">
            <title>Degarelix 200mg (40mg/mL)</title>
            <description>Degarelix 200 mg (40 mg/mL)</description>
          </group>
          <group group_id="O5">
            <title>Degarelix 200mg (60mg/mL)</title>
            <description>Degarelix 200 mg (60 mg/mL)</description>
          </group>
          <group group_id="O6">
            <title>Degarelix 240mg (40mg/mL)</title>
            <description>Degarelix 240 mg (40 mg/mL)</description>
          </group>
          <group group_id="O7">
            <title>Degarelix 240mg (60mg/mL)</title>
            <description>Degarelix 240 mg (60 mg/mL)</description>
          </group>
          <group group_id="O8">
            <title>Degarelix 320mg (60mg/mL)</title>
            <description>Degarelix 320 mg (60 mg/mL)</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With Markedly Abnormal Change in Vital Signs and Body Weight</title>
          <description>Vital signs and body weight included incidence of markedly abnormal changes in blood pressure (systolic and diastolic), pulse, and body weight at the end of trial as compared to baseline. The table presents the number of participants in each group with normal baseline and markedly abnormal value post-baseline.</description>
          <population>ITT population. The first value in the category represents the actual clinical reading and the second is the change from baseline for blood pressure (units: millimeters of mercury) and heart rate (units:beats per minute). The weight category includes participants whose percent weight change from baseline fit the stated ranges.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="24"/>
                <count group_id="O5" value="24"/>
                <count group_id="O6" value="24"/>
                <count group_id="O7" value="24"/>
                <count group_id="O8" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Diastolic blood pressure &lt;=50 and decrease &gt;=15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic blood pressure &gt;=105 and increase &gt;=15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systolic blood pressure &lt;=90 and decrease &gt;=20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systolic blood pressure &gt;=180 and increase &gt;=20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Heart rate &lt;=50 and decrease &gt;=15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Heart rate &gt;=120 and increase &gt;=15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Body weight decrease of &gt;=7 percent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Body weight increase of &gt;=7 percent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Degarelix 120mg (20mg/mL)</title>
          <description>Degarelix 120 mg (20 mg/mL)</description>
        </group>
        <group group_id="E2">
          <title>Degarelix 120mg (40mg/mL)</title>
          <description>Degarelix 120 mg (40 mg/mL)</description>
        </group>
        <group group_id="E3">
          <title>Degarelix 160mg (40mg/mL)</title>
          <description>Degarelix 160 mg (40 mg/mL)</description>
        </group>
        <group group_id="E4">
          <title>Degarelix 200mg (40mg/mL)</title>
          <description>Degarelix 200 mg (40 mg/mL)</description>
        </group>
        <group group_id="E5">
          <title>Degarelix 200mg (60mg/mL)</title>
          <description>Degarelix 200 mg (60 mg/mL)</description>
        </group>
        <group group_id="E6">
          <title>Degarelix 240mg (40mg/mL)</title>
          <description>Degarelix 240 mg (40 mg/mL)</description>
        </group>
        <group group_id="E7">
          <title>Degarelix 240mg (60mg/mL)</title>
          <description>Degarelix 240 mg (60 mg/mL)</description>
        </group>
        <group group_id="E8">
          <title>Degarelix 320mg (60mg/mL)</title>
          <description>Degarelix 320 mg (60 mg/mL)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 7.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2"/>
                <counts group_id="E2" subjects_affected="2"/>
                <counts group_id="E3" subjects_affected="1"/>
                <counts group_id="E4" subjects_affected="2"/>
                <counts group_id="E5" subjects_affected="1"/>
                <counts group_id="E6" subjects_affected="4"/>
                <counts group_id="E7" subjects_affected="3"/>
                <counts group_id="E8" subjects_affected="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Condition aggravated</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatitis toxic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Inervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Metastases to bone</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Metastases to liver</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Metastatic neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Metastatic pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Areflexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Paraplegia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Spinal cord compression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Amputation revision</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 7.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14"/>
                <counts group_id="E2" subjects_affected="10"/>
                <counts group_id="E3" subjects_affected="7"/>
                <counts group_id="E4" subjects_affected="20"/>
                <counts group_id="E5" subjects_affected="14"/>
                <counts group_id="E6" subjects_affected="22"/>
                <counts group_id="E7" subjects_affected="10"/>
                <counts group_id="E8" subjects_affected="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Glaucoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Anal fissure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Stomach discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Feeling of body temperature change</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Injection site induration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Injection site pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Oral fungal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="3" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="3" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Prostatic specific antigen increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="2" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="2" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Nervousness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Nightmare</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nocturia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Erectile dysfunction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="25"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="6" subjects_affected="5" subjects_at_risk="24"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="24"/>
                <counts group_id="E6" events="5" subjects_affected="5" subjects_at_risk="24"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E4" events="12" subjects_affected="12" subjects_at_risk="24"/>
                <counts group_id="E5" events="6" subjects_affected="6" subjects_at_risk="24"/>
                <counts group_id="E6" events="9" subjects_affected="9" subjects_at_risk="24"/>
                <counts group_id="E7" events="4" subjects_affected="4" subjects_at_risk="24"/>
                <counts group_id="E8" events="9" subjects_affected="9" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review the draft manuscript prior to publication and can request delay of publication where any contents are deemed patentable by the sponsor or confidential to the sponsor. Comments will be given within four weeks from receipt of the draft manuscript.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Development Support</name_or_title>
      <organization>Ferring Pharmaceuticals</organization>
      <email>DK0-Disclosure@ferring.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

